Christine D. Mclaughlin

Endocrinology
725 Concord Ave Ste 3300
Cambridge, MA 02138

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

Journal: NPJ precision oncology
Published: September 06, 2025
Showing 1-1 of 1

Last Updated: 09/26/2026